Papargyriou Aristeidis, Najajreh Mulham, Cook David P, Maurer Carlo H, Bärthel Stefanie, Messal Hendrik A, Ravichandran Sakthi K, Richter Till, Knolle Moritz, Metzler Thomas, Shastri Akul R, Öllinger Rupert, Jasper Jacob, Schmidleitner Laura, Wang Surui, Schneeweis Christian, Ishikawa-Ankerhold Hellen, Engleitner Thomas, Mataite Laura, Semina Mariia, Trabulssi Hussein, Lange Sebastian, Ravichandra Aashreya, Schuster Maximilian, Mueller Sebastian, Peschke Katja, Schäfer Arlett, Dobiasch Sophie, Combs Stephanie E, Schmid Roland M, Bausch Andreas R, Braren Rickmer, Heid Irina, Scheel Christina H, Schneider Günter, Zeigerer Anja, Luecken Malte D, Steiger Katja, Kaissis Georgios, van Rheenen Jacco, Theis Fabian J, Saur Dieter, Rad Roland, Reichert Maximilian
Translational Pancreatic Cancer Research Center, Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar, Technical University of Munich, München, Germany.
Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar, Technical University of Munich, München, Germany.
Nat Biomed Eng. 2024 Dec 10. doi: 10.1038/s41551-024-01273-9.
In patients with pancreatic ductal adenocarcinoma (PDAC), intratumoural and intertumoural heterogeneity increases chemoresistance and mortality rates. However, such morphological and phenotypic diversities are not typically captured by organoid models of PDAC. Here we show that branched organoids embedded in collagen gels can recapitulate the phenotypic landscape seen in murine and human PDAC, that the pronounced molecular and morphological intratumoural and intertumoural heterogeneity of organoids is governed by defined transcriptional programmes (notably, epithelial-to-mesenchymal plasticity), and that different organoid phenotypes represent distinct tumour-cell states with unique biological features in vivo. We also show that phenotype-specific therapeutic vulnerabilities and modes of treatment-induced phenotype reprogramming can be captured in phenotypic heterogeneity maps. Our methodology and analyses of tumour-cell heterogeneity in PDAC may guide the development of phenotype-targeted treatment strategies.
在胰腺导管腺癌(PDAC)患者中,肿瘤内和肿瘤间的异质性会增加化疗耐药性和死亡率。然而,PDAC的类器官模型通常无法捕捉到这种形态和表型的多样性。在这里,我们表明,嵌入胶原蛋白凝胶中的分支类器官可以重现小鼠和人类PDAC中所见的表型景观,类器官明显的分子和形态学肿瘤内及肿瘤间异质性由特定的转录程序(特别是上皮-间质可塑性)所控制,并且不同的类器官表型代表了体内具有独特生物学特征的不同肿瘤细胞状态。我们还表明,表型特异性治疗易感性和治疗诱导的表型重编程模式可以在表型异质性图谱中体现。我们对PDAC肿瘤细胞异质性的方法和分析可能会指导针对表型的治疗策略的开发。